Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system

Kaineder, K; Birngruber, T; Rauter, G; Obermuller, B; Eichler, J; Munzker, J; Al-Zoughbi, W; Mautner, S; Torekov, SS; Hartmann, B; Kotzbeck, P; Pieber, TR

Pieber, TR (reprint author), Med Univ Graz, Div Endocrinol & Diabetol, Auenbruggerpl 15, A-8036 Graz, Austria.

INTERNATIONAL JOURNAL OF OBESITY, 2017; 41 (8): 1263

Abstract

BACKGROUND: The GLP-1 receptor agonist liraglutide is marketed for obesity treatment where it induces body weight reduction possibly via the hypothala......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索